Moreover, PD-L1 status in this study was determined based on tumor cell expression only, whereas in the KEYNOTE-059 study of pembrolizumab, PD-L1 status was based on expression on tumor cells and immune cells (ie, combined proportion score) [21], hampering any cross-trial comparison of efficacy trends in GC/GEJC based on PD-L1 status. The gene discussed is CD274; the disease is gastric cancer.